Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management
Summary
Allay Therapeutics raised $57.5 million in Series D financing and secured additional venture debt to advance ATX101 and its ultra-sustained pain platform. The company will use the capital to support its Phase 2b registration trial in post-surgical pain management for total knee replacement patients. Allay also named Joe Zakrzewski as chairman of the board and expanded its Japanese partner Maruishi Pharmaceutical’s license territory to South Korea and Taiwan. The company expects trial data in Q4 2025 and plans a Phase 3 study in 2026.
Funding
Amount
$57.5M
Total raised
Date
June 5, 2025
Announcement date
Investors
Maruishi Pharmaceutical, HSBC, EDBI, New Enterprise Associates, Lightstone Ventures, Vertex Growth, Arboretum Ventures, Vertex Ventures HC
Lead investors
Company
https://www.allaytx.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected